Skip to main content
. 2020 Mar 19;20:235. doi: 10.1186/s12885-020-06750-3

Fig. 1.

Fig. 1

Kaplan-Meier curves for the DFS outcomes among patients with trastuzumab. Patients with low pre-NLR values (group 2) showed higher 3-year DFS compared with that with high pre-NLR values (group 3) (p = 0.003). DFS, disease-free survival; pre-NLR, pretreatment neutrophil/lymphocyte ratio